DHA补充联合家庭饮食咨询对超重肥胖孕妇代谢控制的影响:MIGHT研究
该随机对照试验采用2×2析因设计,纳入1002例孕<15周、BMI≥25 kg/m²的单胎孕妇,评估DHA补充(800或200 mg/d)联合饮食咨询对母婴代谢控制的影响。结果显示联合干预未降低妊娠期糖尿病、巨大儿或新生儿胰岛素抵抗风险(P<.05)。
要点
- 超重肥胖孕妇中DHA联合饮食咨询未降低GDM风险
- 联合干预未减少巨大儿或新生儿胰岛素抵抗
- 坚持DHA补充者脐血血糖水平较低
核心结论
- 对于孕早期超重或肥胖的妇女,DHA补充联合家庭饮食咨询未能降低母亲妊娠期糖尿病风险,也未降低新生儿巨大儿和胰岛素抵抗风险。
研究设计与样本
- 随机对照试验,2×2析因设计,纳入1002例孕<15周、首次产检BMI≥25 kg/m²、单胎、年龄≥18岁的孕妇。
- 随机分为4组:饮食咨询+800 mg/d DHA(n=250);常规咨询+800 mg/d DHA(n=252);饮食咨询+200 mg/d DHA(n=249);常规咨询+200 mg/d DHA(n=251,参照组)。
- 饮食干预共3次课程,重点减少每日糖摄入贡献最大的食物;主要结局为GDM、巨大儿(出生体重>4000 g)和新生儿胰岛素抵抗(脐血HOMA-IR≥2.60,在226例新生儿亚组中评估)。
- 按意向治疗和效力分析;试验注册于ClinicalTrials.gov(NCT02574767)。
主要发现
- 总体GDM发生率为20.2%(组1 21.0%;组2 20.1%;组3 18.9%;组4 20.9%)。
- 平均出生体重3403.0 g(标准差575.3),巨大儿发生率为11.9%(组1 13.2%;组2 10.8%;组3 11.5%;组4 12.1%)。
- 脐血HOMA-IR中位数0.9(四分位距0.6-1.7),10.2%显示脐血胰岛素抵抗(组1 12.0%;组2 12.0%;组3 9.7%;组4 5.1%)。
- 各组主要结局无显著差异(P<.05);坚持DHA补充者脐血血糖浓度较低(P<.05)。
关键数值与推荐
- GDM诊断依据国家指南;巨大儿定义为出生体重>4000 g;新生儿胰岛素抵抗定义为脐血HOMA-IR≥2.60。
- DHA补充剂量为800 mg/d或200 mg/d;饮食咨询共3次课程。
- 主要结局组间比较无显著差异(P<.05);坚持DHA补充者脐血血糖较低(P<.05)。
临床怎么用
- 对于孕早期超重或肥胖妇女,DHA补充联合饮食咨询不应被视为降低GDM、巨大儿或新生儿胰岛素抵抗的有效策略。
- 临床可继续关注DHA补充对脐血血糖的潜在影响,但需进一步研究确认。
局限性
- 新生儿胰岛素抵抗仅在226例新生儿的亚组中评估。
- 原文未报告饮食咨询的具体执行细节和依从性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lifestyle interventions have shown limited effectiveness in the prevention of gestational diabetes mellitus. The combination of lifestyle interventions with omega-3 polyunsaturated fatty acid supplementation could have a synergetic effect on maternal and offspring outcomes. OBJECTIVE: We evaluated the effects of docosahexaenoic acid supplementation among obese and overweight pregnant women (independently or combined with a dietary counseling intervention) on metabolic control in mothers and their offspring. STUDY DESIGN: This study was a randomized controlled trial with a 2×2 factorial design. The following inclusion criteria were used: <15 weeks of gestation; body mass index ≥25 kg/m2 at the first prenatal visit; singleton pregnancy; and 18 years of age or older. The recruited women (n=1002) were randomly allocated to 1 of the 4 parallel groups: Group 1: dietary counseling plus 800 mg/day of docosahexaenoic acid (n=250); Group 2: routine counseling plus 800 mg/day docosahexaenoic acid (n=252); Group 3: dietary counseling plus 200 mg/day docosahexaenoic acid (n=249); and Group 4: routine counseling plus 200 mg/day docosahexaenoic acid (n=251), considered as the reference group. The dietary intervention comprised 3 sessions, and it was focused on reducing the consumption of foods that most contributed to daily sugar intake. Primary outcomes were gestational diabetes mellitus defined according to the national guidelines; macrosomia (birthweight >4000 g); and neonatal insulin resistance (cord blood Homeostasis Model Assessment for Insulin Resistance ≥2.60), which was assessed in a subsample of 226 newborns. The analysis was by intention to treat and by efficacy. The trial was registered on ClinicalTrials.gov (NCT02574767). RESULTS: The overall incidence of gestational diabetes mellitus was 20.2% (Group 1, 21.0%; Group 2, 20.1%; Group 3, 18.9%; and Group 4, 20.9%). Mean birthweight was 3403.0 g (standard deviation, 575.3), and the incidence of macrosomia was 11.9% (Group 1, 13.2%; Group 2, 10.8%; Group 3, 11.5%; and Group 4, 12.1%). Median cord blood Homeostasis Model Assessment for Insulin Resistance was 0.9 (interquartile range, 0.6-1.7), and 10.2% showed cord blood insulin resistance (Group 1, 12.0%; Group 2, 12.0%; Group 3, 9.7%; and Group 4, 5.1%). No significant differences were found among groups regarding primary outcomes (P<.05). Glucose concentrations in the cord blood samples were lower in those adherents to the docosahexaenoic acid supplementation (P<.05). CONCLUSION: For women who were overweight or obese at the beginning of pregnancy, this combined intervention did not reduce the risk of gestational diabetes in mothers or macrosomia and insulin resistance in neonates.
引用
- Garmendia ML, Casanello P, Flores M, et al. The effects of a combined intervention (docosahexaenoic acid supplementation and home-based dietary counseling) on metabolic control in obese and overweight pregnant women: the MIGHT study. Am J Obstet Gynecol. 2020. PMID: 33152314. doi:10.1016/j.ajog.2020.10.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。